Biomarker Predictors of Memantine Sensitivity

What Is This Study About?

This study will test the effects of memantine on brain function and dementia symptoms in older adults with mild to moderate Alzheimer's disease who are not currently taking Alzheimer's medications. Memantine, also known as Namenda, is a drug approved by the U.S. Food and Drug Administration to treat moderate to severe symptoms of Alzheimer's disease. In this study participants will be randomly assigned to take either memantine (20 mg) or a placebo twice daily for about six weeks.

Do I Qualify To Participate in This Study?

Must have:

• Diagnosis of Alzheimer's disease
• Mini-Mental State Examination score of 10 to 22 or Montreal Cognitive Assessment score of 15 to 24
• Knowledgeable caregiver
• Able to walk
• Medically stable
• Pass hearing test

Must NOT have:

• Active systemic illness (e.g., heart disease, liver failure, kidney insufficiency, cancer, HIV, tuberculosis, hepatitis C)
• Current psychiatric or neurological illness other than Alzheimer's disease
• History of vascular disease, heart attack, cerebrovascular accidents, mini-stroke, seizure, head injury with loss of consciousness
• History of substance dependence, including alcohol and opioids
• Past treatment with memantine or unable to take an acetylcholinesterase inhibitor
• Participated in an investigational drug treatment within 30 days of screening
• Prohibited medications: amantadine, riluzole, other pro-cognitive drugs, opioids
• Positive urine test for nonprescribed psychoactive substance
• Actively enrolled in cognitive remediation therapy

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Where Is This Study Located?

California
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center San Diego, CA 92103 Recruiting Jo Talledo, B.A. 619-543-3093 atalledo@ucsd.edu

Who Sponsors This Study?

Lead: University of California, San Diego

Source: ClinicalTrials.gov ID: NCT03703856